



OPEN ACCESS

EDITED BY

Songbai Xu,
First Affiliated Hospital of Jilin University,
Jilin University, China

REVIEWED BY

Tao Xu,
Shanghai Changzheng Hospital, China
Pengfei Ge,
Jilin University, China

*CORRESPONDENCE

Qisheng Tang
✉ tangqisheng@fudan.edu.cn

SPECIALTY SECTION

This article was submitted to
Neuro-Oncology and
Neurosurgical Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 02 December 2022

ACCEPTED 10 January 2023

PUBLISHED 26 January 2023

CITATION

Jiang S, Chai H and Tang Q (2023)
Advances in the intraoperative delineation
of malignant glioma margin.
Front. Oncol. 13:1114450.
doi: 10.3389/fonc.2023.1114450

COPYRIGHT

© 2023 Jiang, Chai and Tang. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Advances in the intraoperative delineation of malignant glioma margin

Shan Jiang, Huihui Chai and Qisheng Tang*

Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

Surgery plays a critical role in the treatment of malignant glioma. However, due to the infiltrative growth and brain shift, it is difficult for neurosurgeons to distinguish malignant glioma margins with the naked eye and with preoperative examinations. Therefore, several technologies were developed to determine precise tumor margins intraoperatively. Here, we introduced four intraoperative technologies to delineate malignant glioma margin, namely, magnetic resonance imaging, fluorescence-guided surgery, Raman histology, and mass spectrometry. By tracing their detecting principles and developments, we reviewed their advantages and disadvantages respectively and imagined future trends.

KEYWORDS

glioma, intraoperative, MRI, FGS, Raman histology, mass spectrometry

Introduction

At present, the standard treatment for malignant glioma is surgical resection combined with chemotherapy and radiotherapy, which is far from reaching patients' expectations and offers slow progress (1–3). As the first step, surgery plays a critical role in multimodal treatments and its efficacy is highly dependent on the surgeon's skill. Moreover, due to the infiltrative growth, it is difficult to depict the tumor margin and excise the tumor completely (4). Consequently, it contributes to a high local relapse rate, and most recurrences occur near the surgery margins. Therefore, delineating more sophisticated brain tumor margins and improving surgeons' ability to navigate removing the tumor completely are important for the improvement of brain tumor treatments (5).

Therefore, to visualize the tumor margin and assist neurosurgeons in resecting tumors completely, establishing a precise and real-time guiding system has already become an active demand in neurosurgery. Besides the infiltrative growth nature, the requirement of protecting brain functional boundaries emphasizes more importance to improving the resolution of margin demarcation than other solid tumors in the peripheral system. Various techniques in detecting tumor molecular or metabolic markers by physical or chemical methods allow for depicting millimeter-level resolution boundaries (6, 7). Moreover, due to the impact of brain shifting, it is necessary for various techniques to be performed and to amend intraoperative detection (8–10).

Here, we list the developments of several novel intraoperative technologies depicting precise malignant brain tumor margins, that is, magnetic resonance imaging (MRI), fluorescence-

guided surgery (FGS), Raman histology, and mass spectrometry (MS) (Figure 1). Analyzing the advantages and disadvantages of different technologies, we provide a comprehensive review to trace the updated developments of new intraoperative systems.

Intraoperative MRI

MRI is the essential preoperative examination for brain cancer patients and a salient basis for intraoperative navigation. However, due to the presence of brain shift, which is inevitably caused by the loss of cerebrospinal fluid, force-induced deformation of brain tissue, and so on, the utilization of preoperative image data to guide neuronavigation will inevitably lead to deviations (11). These deviations may lead to either residual tumor after resection or over-resection of normal brain tissue. Though various software for correction algorithms based on physical or mathematical models are under research and development, clinical examinations of this software are required (12, 13).

Currently, intraoperative imaging remains the established solution (14). Contributing to its high contrast in soft tissues, precise spatial resolution, and functional brain imaging ability, intraoperative MRI (iMRI) becomes the first option among various intraoperative imaging systems (15, 16). The first public application of iMRI in the neurosurgical community was reported by General Electric and Brigham and Women's Hospital (BWH) of Harvard University in 1996 (17, 18). The past 26 years have witnessed a great development in iMRI systems. Previous generations of iMRI were based on moving the operating table into the MRI examination room. Nowadays, fundamental innovations in the engineering and physics of the magnet and coils allow the movement of MRI scanners. The common characteristic of the newest iMRI systems is the performance of intraoperative imaging without the movement of patients, that is, to be able to perform surgery while the scan is being completed and with the patient in the same position (19). The field strength of iMRI is also increasing, which improves the imaging quality. Moreover, high field strength provides the advantages of less signal acquisition time, high sensitivity of functional imaging, and quantitative analysis of tissue metabolites based on spectrum signal (20, 21). Senft et al. performed a prospective, randomized, parallel-group trial to confirm the efficacy of iMRI application. They found that 96% (23/24) of the patients in the iMRI group and 68% (17/25) of the patients in the control group had complete tumor resection. No patient for whom the use of iMRI led to continued resection of the residual tumor had neurological deterioration. It indicated that imaging helped surgeons provide the optimum extent of resection (22). Huashan Hospital retrospectively analyzed 373 patients with 3T iMRI-guided surgery. The ratio of gross total resection for cerebral gliomas ($n = 161$) was increased from 55.90% to 87.58% (23). Also, Kuhnt et al. proved the correlation between the extent of tumor resection and glioblastoma multiforme patient survival with high-field iMRI, demonstrating that navigation guidance and iMRI significantly contribute to optimal EOR with low postoperative morbidity, where the extent of resection $\geq 98\%$ and patient age < 65 years are associated with significant survival advantages (22). However, high-field-strength iMRI has its share of problems. Owing to the interference of waves caused by the dielectric effect,

the imaging signal is uneven and the center signal is higher than the peripheral one. Also, compared with 1.5 T iMRI, motion artifacts, chemical shift artifacts, and susceptibility artifacts were more obvious on 3.0 T iMRI (24).

Besides the structure imaging ability of iMRI, its functional imaging and molecular imaging show more and more advantages in the operation of malignant glioma. The protection of brain function during operation is a very salient issue in neurosurgery. Different from the peripheral system with more clear structural markers, individual brain functional regions have great differences in details. Therefore, electrophysiological monitoring and intraoperative arousal techniques play critical roles in the resection of tumors located in brain functional areas. Usually, preoperative MRI examination uses blood oxygen level-dependent imaging (BOLD) and diffusion tensor imaging (DTI) technologies to achieve fMRI imaging of brain functional areas, to achieve relatively intuitive and gradual delineation of brain functional area boundaries, and to help design surgical approaches and resection schemes. Lehericy et al. and Wu et al. both reported that BOLD localization of the motor cortex was in good agreement with the results of controlled studies on direct electrical stimulation during surgery (25–27). Studies by Rutten et al. show that BOLD and electrical stimulation technology have good consistency in locating the language cortex (28). However, the delineation of malignant glioma functional margin based on preoperative MRI has its limitations. Because of the disturbance in the operation, the accuracy of the preoperative functional partition decreases with the operation. The tiny deviations can have serious consequences when it comes to the functional brain regions. Fortunately, iMRI can achieve both fMRI and DTI. Besides the localization of the motor cortex using the task-based intraoperative fMRI technique during awake procedures, the resting state localizing the motor cortex of patients who are under general anesthesia could be detected using intraoperative fMRI (29, 30). Also, D'Andrea et al. reported that they localized white matter tracts participating in language with intraoperative DTI instead of direct electrical cortical stimulation (DCS) and that 78% of patients achieve gross total excision without any postoperative complications (31). However, the inherent flaws in the functional detection ability of MRI may result in limited statistical power, arbitrary data analysis, false-positive results, and lack of independent replications (32). Therefore, though iMRI could improve the precision of fMRI, the fact that it is time-consuming and unstable makes it unlikely to replace DCS, while intraoperative DTI has the potential to increase the safety and excision extension of non-awake surgery.

Not only functional imaging, but also molecular imaging might be a promising development direction. In 2021, the fifth edition of the WHO Central System Tumor Grading Criteria highlighted the importance of tumor molecular markers as an important basis for classification. As for preoperative MRI, it has already shown its potential in detecting the qualitative, quantitative, and localization of specific molecular chemicals. Magnetic resonance spectroscopy (MRS) is a technology that uses the chemical shift of atomic nucleus caused by the external magnetic field to realize a non-invasive *in vivo* study of physiological or pathological metabolic changes. The hydrogen proton (^1H -MRS) is the most commonly used one. Compared with conventional MRI, ^1H -MRS can determine the nature and value-added activity of lesions from the aspect of

metabolism (33). In the process of occurrence and development of many diseases, the metabolic changes are earlier than the pathological changes (34). Therefore, MRS can distinguish and classify gliomas at the biochemical level (35–37). Roder et al. reported the feasibility of intraoperative MRS and its potential usage in an extended tumor resection (38). However, due to the low spatial resolution, the long examination time, and interference of fat and skull, there is slow progress in the application of intraoperative MRS during surgery. Currently, the mainstream application is to register preoperative MRS imaging into intraoperative MRI, so as to achieve more targeted biopsy or excision guidance (39, 40). More convincing research evidence is needed to support the necessity of carrying out intraoperative MRS.

The application of iMRI also has other limitations. The utilization of iMRI significantly increases operative time compared with traditional operation. It requires additional time for setup, registration, draping, and redraping of patients, as well as the transport of the patient into and out of the scanner (41, 42). It is necessary to take into consideration the additional time needed for patient selection and the scheduling of the operating room. Lastly, the huge cost of iMRI equipment purchase ranges from \$3 million to \$7 million, not including the inconvenient cost of renovating the operative suite (43). Meanwhile, considerable costs are required for the maintenance of iMRI instruments and to employ specialized staff to assist in surgery. Though there was a study demonstrating the potential economic advantages of less hospital stay and lower total hospital costs from using iMRI (44), there is no doubt that the high cost of purchasing an iMRI system has become a major hindrance to universal implementation (43, 45).

Overall, the iMRI system has already been widely applied and exhibits a fantastic prospect. Its high spatial resolution and the depiction of brain function and metabolism margin improve the effect of surgical removal of brain tumors. The future development of iMRI relies on the amelioration of devices and computational performance, including higher magnetic field intensity, higher gradient performance, and multi-channel signal acquisition. The digitally integrated neurosurgical operation center based on iMRI could contribute to interactively integrating a variety of minimally invasive new technologies, to achieve less surgical trauma and more complete surgical resection. Compared with mechanical design, the effect of algorithms and high-performance computers would play a more important role. It is possible to enhance the spatiotemporal resolution of iMRI without the need for magnetic field strength improvement (46, 47). Besides the imaging resolution of brain structures, it is mainly used for determining functional and metabolic boundaries to guide more sophisticated surgical resection.

Intraoperative fluorescence

Another approach to maximize the extent of resection and avoid neurological damage is to use fluorescence dyestuff to highlight tumor regions and improve visual contrast. In recent decades, several fluorescence contrast agents, such as 5-aminolevulinic acid (5-ALA), indocyanine green (ICG), and fluorescein sodium (FLS), have been available for intraoperative use in clinical settings (48, 49).

5-ALA is the precursor of heme synthesis, which can generate protoporphyrin IV (PpIV) during metabolism (50). PpIV has strong photosensitive activity. In malignant tumor cells, the activity of enzymes involved in PpIV production is stronger than that in normal cells, while the activity of enzymes catalyzing the conversion of PpIV to hemochrome is weaker than that in normal cells. Therefore, a large amount of PpIV is accumulated in tumor cells (51, 52). Using this characteristic, the PpIV-rich tumor tissue can emit red fluorescence (635–705 nm) after being irradiated by an appropriate spectrum (407 nm) during the operation. Thus, tumors can be distinguished from normal tissues under the microscope. Therefore, 5-ALA has the advantages of convenient administration (oral administration before surgery), favorable visualization, and repeated administration (53, 54). It was reported that the sensitivity and specificity of 5-ALA in dense HGG tissue were above 90% (55). However, different studies show varying sensitivities (from 21% to 95%) and specificities (from 53% to 100%) (56–60). Meanwhile, 5-ALA is prone to show false-positive results in low-grade glioma, edema, and inflammatory tissues, and the fluorescence signal of deep tumors may also be covered by normal tissues (61–63).

FLS is a fluorescent compound used for obtaining diagnostic biopsies initially. It could be excited by light in the 460- to 500-nm range and send out the yellow-green part of the spectrum between 540 and 690 nm (64). Its application in neurosurgery was pioneered by Moore et al. in 1947 (65). FLS could be intravenously injected and visualized in the tumor tissue through the blood–brain barrier (66). Since the development of microscopes, the dose of FLS frequently used has been 1–2 mg/kg, guaranteeing safety and tolerability (67). Because of its low cost and simple operation, FLS is easy to promote in clinical practice (68). However, it is not directly bound to glioma cells but only accumulates in the tumor tissue; thus, the specificity is lower than that of 5-ALA (69, 70).

Intraoperative Raman histology

Raman histology is a label-free imaging method that uses intrinsic biochemical markers to distinguish tumor tissues (71, 72). In 1928, the Indian physicist Raman found that the inelastic scattering phenomenon occurs when the frequency of an incident photon is shifted after being scattered by a molecule. Therefore, it is possible to identify specific agents according to their unique Raman scattering spectrum (73). Since tumor cells have the ability to change metabolism to promote their rapid proliferation, Raman histology testing the chemical changes (e.g., protein, lipids, nucleic acids, and pH) could assess the tumor margin to guide the resection, based on the chemical composition of both inorganic and biological specimens. Hollon et al. reported that the diagnostic accuracy using stimulated Raman histology in 48 glioma patients was 95.8%. They concluded that the utilization of stimulated Raman histology improved the intraoperative detection of glioma recurrence in near-real time (74).

Considering its characteristics of real-time and rapid detection, intraoperative Raman histology has already shown its potential to achieve real-time molecular pathological level of tumor boundary detection (75). Surface-enhanced Raman scattering (SERS) is a spectroscopic technique based on the plasmon-assisted scattering of molecules absorbed on the noble metal surface, which has high

photostability, sensitivity, and potential for the simultaneous detection of up to 10 compounds (76, 77). Jin et al. reported an intelligent SERS Navigation System to guide brain tumor resection. They detected tumor tissues' metabolic acidosis (pH 6.2–6.9) caused by glucose metabolism shifting from oxidative phosphorylation to aerobic glycolysis. The efficiency had been examined in both animal models and patients. This system accelerates the clinical translation of acidic margin-guided surgery and avoids exogenous imaging probes. Also, concerning its detection of extracellular acidification, which is a common marker in solid tumors and does not rely on specific genetic phenotypes, SERS depiction of solid tumor margin testing metabolic acidosis might have a broader and universal application prospect (78).

However, intraoperative Raman histology has its drawbacks. Firstly, through the spatial resolution at the millimeter level, a small area of each detection range (mm^2) increased the number of repeated operations and the workload of neurosurgeons (79). Meanwhile, *ex vivo* imaging requires tissue removal, which also limits its further clinical application (80). The future development of Raman histology depends on the feasibility of rapid wide-ranging examination and instrument combination with integration and miniaturization.

Intraoperative mass spectrometry

Mass spectrometry is a method of detecting moving ions by separating them according to their mass-to-charge ratios using electric and magnetic fields. The composition of ions can be determined by measuring the exact mass of ions. It is widely used in the laboratory to qualitatively and quantitatively analyze the composition, molecular phenotype, and content of the samples, which has the advantages of high detection speed and high sensitivity (81). The commonly used indicators of glioma detected by mass spectrometry include N-acetylaspartic acid (NAA), 2-hydroxyglutaric acid (2-HG), choline, creatine (Cr), myoinositol (mI), lactic acid (Lac), and lipid (Lip). According to quantitative analysis of certain contents, neurosurgeons could not only distinguish tumor tissue from normal brain tissue but also identify molecular


subtypes of brain tumors (82, 83). For example, the content of NAA reflects the number of neurons and axons, and the concentration of NAA often decreases significantly in brain tumor tissues. 2-HG is the metabolite of *isocitrate dehydrogenase (IDH)* gene mutant glioma; the concentration in *IDH-mutant* tumor samples could be more than 100 times the size of a normal brain tissue (84, 85). The detection of such chemical indicators by intraoperative mass spectrometry provided the ability to characterize the molecular and metabolic boundaries of tumors. Considering its operating principles, the technique applies to a wide range of chemicals and promises high-throughput analysis.

Moreover, in 2004, desorption electrospray ionization mass spectrometry (DESI-MS) made it possible to direct intraoperative sampling analysis without the need for sample preprocessing (86). In 2015, Alan et al. reported that the DESI-MS detections of 158 glioma samples, 223 gray matter samples, and 66 white matter samples could effectively distinguish glioma from white matter and gray matter, and the overall sensitivity and specificity reached 97.4% and 98.5%, respectively (87). Moreover, with the development of techniques, the detection time is reduced to 3 min according to Pirro et al.'s report in 2017 (88).

In a nutshell, intraoperative mass spectrometry has shown the potential to redefine the maximum resection of glioma. Despite its rapid development, the clinical application of iMS remains limited in the operating room, which is essential to complete validation of large-sample-size data. The limitation of spatial resolution and detection accuracy required the development of the ionization technique. The miniaturization of intraoperative simple testing instruments and the establishment of rapid intraoperative testing procedures are the key to accelerate clinical popularization. Also, future development requires more stable biomarkers, a mass spectrometry library, and integrated equipment.

Discussion

We summarized different intraoperative techniques for delineating the precise boundaries of brain tumors, including MRI,



fluorescence-guided surgery, Raman histology, and mass spectrometry. Considering their inability to depict precise boundaries, especially molecular and metabolic margins, we did not include intraoperative computerized tomography and ultrasound in this review. The principle and development of each technique are briefly introduced, and their advantages and disadvantages are analyzed. Regardless of the differences in imaging methods, the ultimate goal of accurate delineation of tumor molecular boundaries is to improve the gross total resection and the surgical benefits for brain tumor patients on the premise of protecting normal brain tissues. At the same time, the delineation of tumor molecular boundaries is helpful to further improve the judgment of molecular classification of brain tumors and guide the subsequent diagnosis and treatment. Though we illustrated them respectively, different techniques were not mutually exclusive; for example, intraoperative mass spectrometry could also be used in conjunction with intraoperative MRI (89). The necessity and priority of the use of different techniques need to be explored and verified. Also, how to interact and fuse multiple methods to form multimodal delineation of tumor boundaries is an important direction for future research and development.

At present, the application of these new technologies is hindered by their high cost. ElGamal et al. have analyzed the effectiveness and cost-effectiveness of intraoperative fluorescence, intraoperative ultrasound, and intraoperative MRI (90). All approaches have been shown to significantly improve the gross total resection and progression-free survival of high-grade gliomas, while the high cost of these new techniques has significantly hindered the progress and prevalence of these techniques. Therefore, cost reduction and the improvement of integrated and miniaturized intraoperative detection equipment are urgent problems that need to be solved in future engineering and manufacturing development. To promote the popularization of these new technology, it requires to be compatible with common operating rooms. One possible solution to strike balance between accuracy and economic efficiency is to establish a large-sample multimodal database and use artificial intelligence algorithms to improve the original imaging resolution (91–93).

Based on the criteria of intraoperative real-time imaging and delineation of tumor boundaries at the molecular level, we selected intraoperative MRI, fluorescence-guided surgery, Raman histology, and mass spectrometry for review. Due to the rapid development of technology and the differences in different regions, inevitably, the

tracking of new technologies is not timely. Based on physical and chemical principles, advances in mechanical engineering and computer technology make it possible to apply these theories to delineate tumor molecular boundaries in operating rooms. We firmly believe that these multidisciplinary advances and integrated applications drive the continuous progress of medical treatment. The continuous cultivation of these methods also continuously updates our understanding of cancer and innovates our diagnosis and treatment methods, to effectively protect the life and health of patients.

Author contributions

SJ wrote the first draft of the manuscript. HC revised the manuscript and was in charge of language editing. QT reviewed and edited the final manuscript. All authors contributed to the article and approved the submitted version.

Funding

This article was supported by the Shanghai Science and Technology Committee Rising-Star Program(20QA1401900) and National Natural Science Foundation of China (82072020).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. McBain C, Lawrie TA, Rogozinska E, Kernohan A, Robinson T, Jefferies S. Treatment options for progression or recurrence of glioblastoma: A network meta-analysis. *Cochrane Database Syst Rev* (2021) 5:CD013579. doi: 10.1002/14651858.CD013579.pub2
2. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: Standard of care and future directions. *J Clin Oncol* (2007) 25(26):4127–36. doi: 10.1200/JCO.2007.11.8554
3. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. *Nat Rev Dis Primers* (2015) 1:15017. doi: 10.1038/nrdp.2015.17
4. Krivosheya D, Prabhu SS, Weinberg JS, Sawaya R. Technical principles in glioma surgery and preoperative considerations. *J Neurooncol* (2016) 130(2):243–52. doi: 10.1007/s11060-016-2171-4
5. Brown TJ, Brennan MC, Li M, Church EW, Brandmeier NJ, Rakszawski KL, et al. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. *JAMA Oncol* (2016) 2(11):1460–9. doi: 10.1001/jamaoncol.2016.1373
6. Cakmakci D, Kaynar G, Bund C, Piotto M, Proust F, Namer IJ, et al. Targeted metabolomics analyses for brain tumor margin assessment during surgery. *Bioinformatics* (2022) 38(12):3238–44. doi: 10.1093/bioinformatics/btac309
7. Alieva M, Leidgens V, Riemenschneider MJ, Klein CA, Hau P, van Rheenen J. Intravital imaging of glioma border morphology reveals distinctive cellular dynamics and contribution to tumor cell invasion. *Sci Rep* (2019) 9(1):2054. doi: 10.1038/s41598-019-38625-4
8. Gerard IJ, Kersten-Oertel M, Petrecca K, Sirhan D, Hall JA, Collins DL. Brain shift in neuronavigation of brain tumors: A review. *Med Image Anal* (2017) 35:403–20. doi: 10.1016/j.media.2016.08.007

9. Phillips HW, Maniquis CAB, Chen JS, Duby SL, Nagahama Y, Bergeron D, et al. Midline brain shift after hemispheric surgery: Natural history, clinical significance, and association with cerebrospinal fluid movement. *Oper Neurosurg (Hagerstown)* (2022) 22 (5):269–76. doi: 10.1227/ons.0000000000000134
10. Pallavaram S, Dawant BM, Rempel MS, Neimat JS, Kao C, Konrad PE, et al. Effect of brain shift on the creation of functional atlases for deep brain stimulation surgery. *Int J Comput Assist Radiol Surg* (2010) 5(3):221–8. doi: 10.1007/s11548-009-0391-1
11. Luo M, Narasimhan S, Larson PS, Martin AJ, Konrad PE, Miga MI. Impact of brain shift on neural pathways in deep brain stimulation: A preliminary analysis Via multi-physics finite element models. *J Neural Eng* (2021) 18(5). doi: 10.1088/1741-2552/abf066
12. Lesage AC, Simmons A, Sen A, Singh S, Chen M, Cazoulat G, et al. Viscoelastic biomechanical models to predict inward brain-shift using public benchmark data. *Phys Med Biol* (2021) 66(20). doi: 10.1088/1361-6560/ac22dc
13. Hu J, Jin X, Lee JB, Zhang L, Chaudhary V, Guthikonda M, et al. Intraoperative brain shift prediction using a 3d inhomogeneous patient-specific finite element model. *J Neurosurg* (2007) 106(1):164–9. doi: 10.3171/jns.2007.106.1.164
14. Kuhnt D, Bauer MH, Nimsky C. Brain shift compensation and neurosurgical image fusion using intraoperative mri: Current status and future challenges. *Crit Rev BioMed Eng* (2012) 40(3):175–85. doi: 10.1615/critrevbiomedeng.v40.i3.20
15. Villanueva-Meyer JE, Mabray MC, Cha S. Current clinical brain tumor imaging. *Neurosurgery* (2017) 81(3):397–415. doi: 10.1093/neuros/nyx103
16. Fink JR, Muzi M, Peck M, Krohn KA. Multimodality brain tumor imaging: Mr imaging, pet, and Pet/Mr imaging. *J Nucl Med* (2015) 56(10):1554–61. doi: 10.2967/jnumed.113.131516
17. Black PM, Moriarty T, Alexander E3rd, Stieg P, Woodard EJ, Gleason PL, et al. Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. *Neurosurgery* (1997) 41(4):831–42. doi: 10.1097/00006123-199710000-00013
18. Black P, Jolesz FA, Medani K. From vision to reality: The origins of intraoperative Mr imaging. *Acta Neurochir Suppl* (2011) 109:3–7. doi: 10.1007/978-3-211-99651-5_1
19. Rogers CM, Jones PS, Weinberg JS. Intraoperative mri for brain tumors. *J Neurooncol* (2021) 151(3):479–90. doi: 10.1007/s11060-020-03667-6
20. Hespel AM, Cole RC. Advances in high-field mri. *Vet Clin North Am Small Anim Pract* (2018) 48(1):11–29. doi: 10.1016/j.cvsm.2017.08.002
21. Cattarinussi G, Delvecchio G, Maggioni E, Bressi C, Brambilla P. Ultra-high field imaging in major depressive disorder: A review of structural and functional studies. *J Affect Disord* (2021) 290:65–73. doi: 10.1016/j.jad.2021.04.056
22. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative mri guidance and extent of resection in glioma surgery: A randomised, controlled trial. *Lancet Oncol* (2011) 12(11):997–1003. doi: 10.1016/S1470-2045(11)70196-6
23. Qiu TM, Yao CJ, Wu JS, Pan ZG, Zhuang DX, Xu G, et al. Clinical experience of 3t intraoperative magnetic resonance imaging integrated neurosurgical suite in shanghai huashan hospital. *Chin Med J (Engl)* (2012) 125(24):4328–33.
24. Roder C, Haas P, Tatagiba M, Ernemann U, Bender B. Technical limitations and pitfalls of diffusion-weighted imaging in intraoperative high-field mri. *Neurosurg Rev* (2021) 44(1):327–34. doi: 10.1007/s10143-019-01206-0
25. Lehericy S, Duffau H, Cornu P, Capelle L, Pidoux B, Carpentier A, et al. Correspondence between functional magnetic resonance imaging somatotopy and individual brain anatomy of the central region: Comparison with intraoperative stimulation in patients with brain tumors. *J Neurosurg* (2000) 92(4):589–98. doi: 10.3171/jns.2000.92.4.0589
26. Leclercq D, Duffau H, Delmaire C, Capelle L, Gatignol P, Ducros M, et al. Comparison of diffusion tensor imaging tractography of language tracts and intraoperative subcortical stimulations. *J Neurosurg* (2010) 112(3):503–11. doi: 10.3171/2009.8.JNS09558
27. Ghinda D, Zhang N, Lu J, Yao CJ, Yuan S, Wu JS. Contribution of combined intraoperative electrophysiological investigation with 3-T intraoperative mri for awake cerebral glioma surgery: Comprehensive review of the clinical implications and radiological outcomes. *Neurosurg Focus* (2016) 40(3):E14. doi: 10.3171/2015.12.FOCUS15572
28. Rutten GJ, Ramsey NF, van Rijen PC, Noordmans HJ, van Veelen CW. Development of a functional magnetic resonance imaging protocol for intraoperative localization of critical temporoparietal language areas. *Ann Neurol* (2002) 51(3):350–60. doi: 10.1002/ana.10117
29. Gasser T, Ganslandt O, Sandalcioğlu E, Stolke D, Fahlbusch R, Nimsky C. Intraoperative functional mri: Implementation and preliminary experience. *Neuroimage* (2005) 26(3):685–93. doi: 10.1016/j.neuroimage.2005.02.022
30. Qiu TM, Gong FY, Gong X, Wu JS, Lin CP, Biswal BB, et al. Real-time motor cortex mapping for the safe resection of glioma: An intraoperative resting-state fmri study. *AJNR Am J Neuroradiol* (2017) 38(11):2146–52. doi: 10.3174/ajnr.A5369
31. D'Andrea G, Familiari P, Di Lauro A, Angelini A, Sessa G. Safe resection of gliomas of the dominant angular gyrus availing of preoperative fmri and intraoperative dti: Preliminary series and surgical technique. *World Neurosurg* (2016) 87:627–39. doi: 10.1016/j.wneu.2015.10.076
32. Poldrack RA, Baker CI, Durnez J, Gorgolewski KJ, Matthews PM, Munafò MR, et al. Scanning the horizon: Towards transparent and reproducible neuroimaging research. *Nat Rev Neurosci* (2017) 18(2):115–26. doi: 10.1038/nrn.2016.167
33. Rich LJ, Bagga P, Wilson NE, Schnall MD, Detre JA, Haris M, et al. (1)H magnetic resonance spectroscopy of (2)H-to-(1)H exchange quantifies the dynamics of cellular metabolism in vivo. *Nat BioMed Eng* (2020) 4(3):335–42. doi: 10.1038/s41551-019-0499-8
34. Nakahara T, Tsugawa S, Noda Y, Ueno F, Honda S, Kinjo M, et al. Glutamatergic and gabaergic metabolite levels in schizophrenia-spectrum disorders: A meta-analysis of (1)H-magnetic resonance spectroscopy studies. *Mol Psychiatry* (2022) 27(1):744–57. doi: 10.1038/s41380-021-01297-6
35. Branzoli F, Marjanska M. Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: Current knowledge on the neurochemical profile. *Curr Opin Neurol* (2020) 33(4):413–21. doi: 10.1097/WCO.0000000000000833
36. Ruiz-Rodado V, Brender JR, Cherukuri MK, Gilbert MR, Larion M. Magnetic resonance spectroscopy for the study of CNS malignancies. *Prog Nucl Magn Reson Spectrosc* (2021) 122:23–41. doi: 10.1016/j.pnmrs.2020.11.001
37. Hwang JH, Choi CS. Use of in vivo magnetic resonance spectroscopy for studying metabolic diseases. *Exp Mol Med* (2015) 47:e139. doi: 10.1038/emmm.2014.101
38. Roder C, Skardelly M, Ramina KF, Beschoner R, Honneger J, Nagele T, et al. Spectroscopy imaging in intraoperative Mr suite: Tissue characterization and optimization of tumor resection. *Int J Comput Assist Radiol Surg* (2014) 9(4):551–9. doi: 10.1007/s11548-013-0952-1
39. Grech-Sollars M, Vaqas B, Thompson G, Barwick T, Honeyfield L, O'Neill K, et al. An Mrs- and pet-guided biopsy tool for intraoperative neuronavigational systems. *J Neurosurg* (2017) 127(4):812–818. doi: 10.3171/2016.7.JNS16106
40. Zhang J, Zhuang DX, Yao CJ, Lin CP, Wang TL, Qin ZY, et al. Metabolic approach for tumor delineation in glioma surgery: 3d Mr spectroscopy image-guided resection. *J Neurosurg* (2016) 124(6):1585–93. doi: 10.3171/2015.6.JNS142651
41. Lu CY, Chen XL, Chen XL, Fang XJ, Zhao YL. Clinical application of 3.0 T intraoperative magnetic resonance combined with multimodal neuronavigation in resection of cerebral eloquent area glioma. *Med (Baltimore)* (2018) 97(34):e11702. doi: 10.1097/MD.00000000000011702
42. Berkow LC. Anesthetic management and human factors in the intraoperative mri environment. *Curr Opin Anaesthesiol* (2016) 29(5):563–7. doi: 10.1097/ACO.0000000000000366
43. Abraham P, Sarkar R, Brandel MG, Wali AR, Rennert RC, Lopez Ramos C, et al. Cost-effectiveness of intraoperative mri for treatment of high-grade gliomas. *Radiology* (2019) 291(3):689–97. doi: 10.1148/radiol.2019182095
44. Hall WA, Kowalik K, Liu H, Truwit CL, Kucharczyk J. Costs and benefits of intraoperative Mr-guided brain tumor resection. *Acta Neurochir Suppl* (2003) 85:137–42. doi: 10.1007/978-3-7091-6043-5_19
45. Bettmann MA. Intraoperative mri for treatment of high-grade glioma: Is it cost-effective? *Radiology* (2019) 291(3):698–9. doi: 10.1148/radiol.2019190337
46. Zhao C, Dewey BE, Pham DL, Calabresi PA, Reich DS, Prince JL. Smore: A self-supervised anti-aliasing and super-resolution algorithm for mri using deep learning. *IEEE Trans Med Imaging* (2021) 40(3):805–17. doi: 10.1109/TMI.2020.3037187
47. Johnson PM, Recht MP, Knoll F. Improving the speed of mri with artificial intelligence. *Semin Musculoskelet Radiol* (2020) 24(1):12–20. doi: 10.1055/s-0039-3400265
48. Orillac C, Stummer W, Orringer DA. Fluorescence guidance and intraoperative adjuvants to maximize extent of resection. *Neurosurgery* (2021) 89(5):727–36. doi: 10.1093/neuros/nyaa475
49. Shen B, Zhang Z, Shi X, Cao C, Zhang Z, Hu Z, et al. Real-time intraoperative glioma diagnosis using fluorescence imaging and deep convolutional neural networks. *Eur J Nucl Med Mol Imaging* (2021) 48(11):3482–92. doi: 10.1007/s00259-021-05326-y
50. Rehani PR, Iftikhar H, Nakajima M, Tanaka T, Jabbar Z, Rehani RN. Safety and mode of action of diabetes medications in comparison with 5-aminolevulinic acid (5-ala). *J Diabetes Res* (2019) 2019:4267357. doi: 10.1155/2019/4267357
51. Bunk EC, Wagner A, Stummer W, Sennar V, Bröckel B. 5-ala kinetics in meningiomas: Analysis of tumor fluorescence and ppix metabolism in vitro and comparative analyses with high-grade gliomas. *J Neurooncol* (2021) 152(1):37–46. doi: 10.1007/s11060-020-03680-9
52. Jones PS, Yekula A, Lansbury E, Small JL, Ayinon C, Mordecai S, et al. Characterization of plasma-derived protoporphyrin-ix-Positive extracellular vesicles following 5-ala use in patients with malignant glioma. *EBioMedicine* (2019) 48:23–35. doi: 10.1016/j.ebiom.2019.09.025
53. Diez Valle R, Hadjipanayis CG, Stummer W. Established and emerging uses of 5-ala in the brain: An overview. *J Neurooncol* (2019) 141(3):487–94. doi: 10.1007/s11060-018-03087-7
54. Michael AP, Watson VL, Ryan D, Delfino KR, Bekker SV, Cozzens JW. Effects of 5-ala dose on resection of glioblastoma. *J Neurooncol* (2019) 141(3):523–31. doi: 10.1007/s11060-019-03100-7
55. Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? *Neurosurgery* (2015) 77(5):663–73. doi: 10.1227/NEU.0000000000000929
56. Gessler F, Forster MT, Duetzmann S, Mittelbronn M, Hattingen E, Franz K, et al. Combination of intraoperative magnetic resonance imaging and intraoperative fluorescence to enhance the resection of contrast enhancing gliomas. *Neurosurgery* (2015) 77(1):16–22. doi: 10.1227/NEU.0000000000000729
57. Coburger J, Scheuerle A, Pala A, Thal D, Wirtz CR, König R. Histopathological insights on imaging results of intraoperative magnetic resonance imaging, 5-

- aminolevulinic acid, and intraoperative ultrasound in glioblastoma surgery. *Neurosurgery* (2017) 81(1):165–74. doi: 10.1093/neuros/nyw143
58. Valdes PA, Jacobs V, Harris BT, Wilson BC, Leblond F, Paulsen KD, et al. Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin ix biomarker as a surgical adjunct in low-grade glioma surgery. *J Neurosurg* (2015) 123(3):771–80. doi: 10.3171/2014.12.JNS14391
59. Kiesel B, Mischkulnig M, Woehrer A, Martinez-Moreno M, Millesi M, Mallouhi A, et al. Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas. *J Neurosurg* (2018) 129(2):341–53. doi: 10.3171/2017.4.JNS162991
60. Valdes PA, Roberts DW, Lu FK, Golby A. Optical technologies for intraoperative neurosurgical guidance. *Neurosurg Focus* (2016) 40(3):E8. doi: 10.3171/2015.12.FOCUS15550
61. Kiesel B, Freund J, Reichert D, Wadiura L, Erkkilae MT, Woehrer A, et al. 5-ala in suspected low-grade gliomas: Current role, limitations, and new approaches. *Front Oncol* (2021) 11:699301. doi: 10.3389/fonc.2021.699301
62. Almekkawi AK, El Ahmadih TY, Wu EM, Abunimer AM, Abi-Aad KR, Aoun SG, et al. The use of 5-aminolevulinic acid in low-grade glioma resection: A systematic review. *Oper Neurosurg (Hagerstown)* (2020) 19(1):1–8. doi: 10.1093/ons/npz336
63. Hosmann A, Millesi M, Wadiura LI, Kiesel B, Mercea PA, Mischkulnig M, et al. 5-ala fluorescence is a powerful prognostic marker during surgery of low-grade gliomas (Who grade ii)-experience at two specialized centers. *Cancers (Basel)* (2021) 13(11):2540. doi: 10.3390/cancers13112540
64. Waqas M, Shamim MS. Sodium fluorescein guided resection of malignant glioma. *J Pak Med Assoc* (2018) 68(6):968–70.
65. Schebesch KM, Brawanski A, Hohenberger C, Hohne J. Fluorescein sodium-guided surgery of malignant brain tumors: History, current concepts, and future project. *Turk Neurosurg* (2016) 26(2):185–94. doi: 10.5137/1019-5149.JTN.16952-16.0
66. Folaron M, Strawbridge R, Samkoe KS, Filan C, Roberts DW, Davis SC. Elucidating the kinetics of sodium fluorescein for fluorescence-guided surgery of glioma. *J Neurosurg* (2018) 131(3):724–34. doi: 10.3171/2018.4.JNS172644
67. Fan C, Jiang Y, Liu R, Wu G, Wu G, Xu K, et al. Safety and feasibility of low-dose fluorescein-guided resection of glioblastoma. *Clin Neurol Neurosurg* (2018) 175:57–60. doi: 10.1016/j.clineuro.2018.10.011
68. Bowden SG, Neira JA, Gill BJA, Ung TH, Englander ZK, Zanazzi G, et al. Sodium fluorescein facilitates guided sampling of diagnostic tumor tissue in nonenhancing gliomas. *Neurosurgery* (2018) 82(5):719–27. doi: 10.1093/neuros/nyx271
69. Schwake M, Stummer W, Suero Molina EJ, Wolfer J. Simultaneous fluorescein sodium and 5-ala in fluorescence-guided glioma surgery. *Acta Neurochir (Wien)* (2015) 157(5):877–9. doi: 10.1007/s00701-015-2401-0
70. Hansen RW, Pedersen CB, Halle B, Korshoej AR, Schulz MK, Kristensen BW, et al. Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: A single-center retrospective study. *J Neurosurg* (2019) 133(5):1324–1331. doi: 10.3171/2019.6.JNS191531
71. Di L, Eichberg DG, Huang K, Shah AH, Jamshidi AM, Luther EM, et al. Stimulated raman histology for rapid intraoperative diagnosis of gliomas. *World Neurosurg* (2021) 150:e135–e43. doi: 10.1016/j.wneu.2021.02.122
72. Hollon T, Orringer DA. Label-free brain tumor imaging using raman-based methods. *J Neurooncol* (2021) 151(3):393–402. doi: 10.1007/s11060-019-03380-z
73. Yui H. Electron-enhanced raman scattering: A history of its discovery and spectroscopic applications to solution and interfacial chemistry. *Anal Bioanal Chem* (2010) 397(3):1181–90. doi: 10.1007/s00216-010-3703-y
74. Hollon TC, Pandian B, Urias E, Save AV, Adapa AR, Srinivasan S, et al. Rapid, label-free detection of diffuse glioma recurrence using intraoperative stimulated raman histology and deep neural networks. *Neuro Oncol* (2021) 23(1):144–55. doi: 10.1093/neonc/noaa162
75. Hollon TC, Pandian B, Adapa AR, Urias E, Save AV, Khalsa SSS, et al. Near real-time intraoperative brain tumor diagnosis using stimulated raman histology and deep neural networks. *Nat Med* (2020) 26(1):52–8. doi: 10.1038/s41591-019-0715-9
76. Spedalieri C, Kneipp J. Surface enhanced raman scattering for probing cellular biochemistry. *Nanoscale* (2022) 14(14):5314–28. doi: 10.1039/d2nr00449f
77. Vendrell M, Maiti KK, Dhaliwal K, Chang YT. Surface-enhanced raman scattering in cancer detection and imaging. *Trends Biotechnol* (2013) 31(4):249–57. doi: 10.1016/j.tibtech.2013.01.013
78. Jin Z, Yue Q, Duan W, Sui A, Zhao B, Deng Y, et al. Intelligent sers navigation system guiding brain tumor surgery by intraoperatively delineating the metabolic acidosis. *Adv Sci (Weinh)* (2022) 9(7):e2104935. doi: 10.1002/advs.202104935
79. Hollon T, Stummer W, Orringer D, Suero Molina E. Surgical adjuncts to increase the extent of resection: Intraoperative mri, fluorescence, and raman histology. *Neurosurg Clin N Am* (2019) 30(1):65–74. doi: 10.1016/j.nec.2018.08.012
80. Hubbard TJE, Shore A, Stone N. Raman spectroscopy for rapid intra-operative margin analysis of surgically excised tumour specimens. *Analyst* (2019) 144(22):6479–96. doi: 10.1039/c9an01163c
81. Santilli AML, Ren K, Oleschuk R, Kaufmann M, Rudan J, Fichtinger G, et al. Application of intraoperative mass spectrometry and data analytics for oncological margin detection, a review. *IEEE Trans BioMed Eng* (2022) 69(7):2220–32. doi: 10.1109/TBME.2021.3139992
82. Neidert MC, Bozinov O. Mass spectrometry-based intraoperative tissue identification in neurosurgery. *World Neurosurg* (2013) 80(6):683–4. doi: 10.1016/j.wneu.2013.10.027
83. Parry PV, Engh JA. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. *Neurosurgery* (2013) 72(4):N17–8. doi: 10.1227/01.neu.0000428422.82081.62
84. Chen R, Brown HM, Cooks RG. Metabolic profiles of human brain parenchyma and glioma for rapid tissue diagnosis by targeted desorption electrospray ionization mass spectrometry. *Anal Bioanal Chem* (2021) 413(25):6213–24. doi: 10.1007/s00216-021-03593-0
85. Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, et al. Early noninvasive metabolic biomarkers of mutant idh inhibition in glioma. *Metabolites* (2021) 11(2):109. doi: 10.3390/metabo11020109
86. Takats Z, Wiseman JM, Gologan B, Cooks RG. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. *Science* (2004) 306(5695):471–3. doi: 10.1126/science.1104404
87. Jarmusch AK, Pirro V, Baird Z, Hattab EM, Cohen-Gadol AA, Cooks RG. Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization-Ms. *Proc Natl Acad Sci U S A* (2016) 113(6):1486–91. doi: 10.1073/pnas.1523306113
88. Pirro V, Alfaro CM, Jarmusch AK, Hattab EM, Cohen-Gadol AA, Cooks RG. Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. *Proc Natl Acad Sci U S A* (2017) 114(26):6700–5. doi: 10.1073/pnas.1706459114
89. Letertre MPM, Dervilly G, Giraudeau P. Combined nuclear magnetic resonance spectroscopy and mass spectrometry approaches for metabolomics. *Anal Chem* (2021) 93(1):500–18. doi: 10.1021/acs.analchem.0c04371
90. Eljamel MS, Mahboob SO. The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ala, fluorescein, ultrasound and mri. *Photodiagnosis Photodyn Ther* (2016) 16:35–43. doi: 10.1016/j.pdpdt.2016.07.012
91. Leclerc P, Ray C, Mahieu-Williams L, Alston L, Frindel C, Brevet PF, et al. Machine learning-based prediction of glioma margin from 5-ala induced ppix fluorescence spectroscopy. *Sci Rep* (2020) 10(1):1462. doi: 10.1038/s41598-020-58299-7
92. Cakmakci D, Karakaslar EO, Ruhland E, Chenard MP, Proust F, Piotto M, et al. Machine learning assisted intraoperative assessment of brain tumor margins using hrmas nmr spectroscopy. *PLoS Comput Biol* (2020) 16(11):e1008184. doi: 10.1371/journal.pcbi.1008184
93. Marsden M, Weyers BW, Bec J, Sun T, Gandour-Edwards RF, Birkeland AC, et al. Intraoperative margin assessment in oral and oropharyngeal cancer using label-free fluorescence lifetime imaging and machine learning. *IEEE Trans BioMed Eng* (2021) 68(3):857–68. doi: 10.1109/TBME.2020.3010480